Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 2,102.4 237.5 885.3% View Chart
P/BV x 27.9 11.9 233.9% View Chart
Dividend Yield % 1.6 1.3 119.3%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
GSK PHARMA
Mar-19
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs9803,595 27.3%   
Low Rs6001,253 47.9%   
Sales per share (Unadj.) Rs198.7184.7 107.6%  
Earnings per share (Unadj.) Rs21.026.3 79.7%  
Cash flow per share (Unadj.) Rs22.329.2 76.3%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.30.8 153.4%  
Book value per share (Unadj.) Rs307.5126.3 243.4%  
Shares outstanding (eoy) m24.69169.40 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.013.1 30.3%   
Avg P/E ratio x37.792.2 40.9%  
P/CF ratio (eoy) x35.583.1 42.7%  
Price / Book Value ratio x2.619.2 13.4%  
Dividend payout %47.776.1 62.7%   
Avg Mkt Cap Rs m19,508410,626 4.8%   
No. of employees `0000.65.0 11.7%   
Total wages/salary Rs m1,1715,372 21.8%   
Avg. sales/employee Rs Th8,445.46,306.7 133.9%   
Avg. wages/employee Rs Th2,015.71,083.1 186.1%   
Avg. net profit/employee Rs Th891.0898.0 99.2%   
INCOME DATA
Net Sales Rs m4,90731,281 15.7%  
Other income Rs m7831,023 76.5%   
Total revenues Rs m5,68932,304 17.6%   
Gross profit Rs m1236,009 2.0%  
Depreciation Rs m32486 6.5%   
Interest Rs m166 265.0%   
Profit before tax Rs m8586,540 13.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3402,373 14.3%   
Profit after tax Rs m5184,454 11.6%  
Gross profit margin %2.519.2 13.0%  
Effective tax rate %39.636.3 109.3%   
Net profit margin %10.614.2 74.1%  
BALANCE SHEET DATA
Current assets Rs m8,05520,061 40.1%   
Current liabilities Rs m1,85014,543 12.7%   
Net working cap to sales %126.417.6 716.8%  
Current ratio x4.41.4 315.6%  
Inventory Days Days4557 79.3%  
Debtors Days Days3414 241.2%  
Net fixed assets Rs m15014,343 1.0%   
Share capital Rs m1231,694 7.3%   
"Free" reserves Rs m7,46919,704 37.9%   
Net worth Rs m7,59221,398 35.5%   
Long term debt Rs m02 0.0%   
Total assets Rs m9,82439,113 25.1%  
Interest coverage x54.91,091.0 5.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 62.4%   
Return on assets %5.411.4 47.6%  
Return on equity %6.820.8 32.8%  
Return on capital %11.531.9 36.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m58534 10.8%   
Fx outflow Rs m1,3267,091 18.7%   
Net fx Rs m-1,269-6,557 19.3%   
CASH FLOW
From Operations Rs m-1,9433,994 -48.6%  
From Investments Rs m2,742-1,433 -191.3%  
From Financial Activity Rs m-298-3,584 8.3%  
Net Cashflow Rs m501-1,023 -49.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 120 Points Higher; Dow Futures Down by 47 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 120 points, up 0.3%, at 40,678 levels.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

PSU Stocks Are Looking Positive Now(Fast Profits Daily)

Oct 19, 2020

Has the market changed its opinion on PSUs?

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 23, 2020 03:36 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS